Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab DDI Study with Midazolam in Psoriasis
NCT02607774Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration at Day 36, Area Under the Curve 0-12h at Day 36 and 2 more. Started Dec 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02607774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607774.